Drug Policy in Hungary Value in Health Regional Issues

Slides:



Advertisements
Similar presentations
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Advertisements

Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Value and Service Quality Assessment of the National Health Insurance Scheme in Ghana: Evidence from Ashiedu Keteke District  Eric Nsiah-Boateng, MSc,
Value in Health Regional Issues
Investigating the Economic Impacts of New Public Pharmaceutical Policies in Greece: Focusing on Price Reductions and Cost-Sharing Rates  Siskou Ch. Olga,
Value in Health Regional Issues
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
Value and Service Quality Assessment of the National Health Insurance Scheme in Ghana: Evidence from Ashiedu Keteke District  Eric Nsiah-Boateng, MSc,
An Audit of Diabetes-Dependent Quality of Life (ADDQOL) in Older Patients with Diabetes Mellitus Type 2 in Slovenia  Eva Turk, MA, MBA, Valentina Prevolnik.
The Development of the Romanian Scorecard HTA System
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Value in Health Regional Issues
Drug Policy in Slovakia
Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
From Regulatory Approval to Subsidized Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand,
Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007–2010)  Rok Hren, PhD,
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan  Kaoru Yamabe, MSc, Puneet K. Singhal,
Drug Policy in Croatia Value in Health Regional Issues
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs)
The Process of Privatization of Health Care Provision in Poland
Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
Drug Policy in Bulgaria
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective.
Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary  Zoltán Kaló, MSc, MD, PhD, József Bodrogi, MSc, Imre Boncz,
Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm 
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India  S.K.R. Sowmya, PharmD, Dixon.
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems  Randall Winnette, MSc, Victor Zárate, MD, MSc,
Advancing the Visibility, Impact, and Quality Metrics of Value in Health Regional Issues  Dan Greenberg, PhD, Imre Boncz, MD, MSc, PhD, Habil, Ahmed Awaisu,
Omneya Mohamed, PhD, David H. Kreling, PhD 
Drug Policy in the Czech Republic
Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?  Fei-Li.
A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations  Panagiotis Petrou, MBA, PhD, PhDc, Michalis.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Volume 130, Issue 6, (September 2007)
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries  Travor Mabugu,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Cost-Effectiveness Analysis Expands its Reach Worldwide
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Guidance Document: Global Pharmacoeconomic Model Adaption Strategies
Jing Wu, PhD, Ning Yue, MS, Weiwei Xu, PhD 
HTA and Its Use in Drug Policies: Singapore
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making  Roza Ismailovna Yagudina, PhD, Andrey Urievich.
Colombian Health System on its Way to Improve Allocation Efficiency—Transition from a Health Sector Reform to the Settlement of an HTA Agency  Nicolás.
Value in Health Regional Issues
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
The Drug Reimbursement Decision-Making System in Iran
Social Cost of Substance Abuse in Russia
Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia  Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.
Victoria I. Ignatyeva, MPH, Johan L
Evaluation of Quality of Pharmacoeconomic Studies in Asia-Pacific Region and Identification of Influencing Variables  Prabhakar Pandey, MPharm, Rishabh.
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Drug Policy in Hungary Value in Health Regional Issues András Inotai, PharmD, PhD, Marcell Csanádi, MSc, András Harsányi, MSc, Bertalan Németh, MSc  Value in Health Regional Issues  Volume 13, Pages 16-22 (September 2017) DOI: 10.1016/j.vhri.2017.06.003 Copyright © 2017 Terms and Conditions

Fig. 1 The general reimbursement decision-making process in Hungary in the case of pharmaceuticals [17]. HTA, health technology assessment; NHIF, National Health Insurance Fund. Value in Health Regional Issues 2017 13, 16-22DOI: (10.1016/j.vhri.2017.06.003) Copyright © 2017 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.